Citation Impact
Citing Papers
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
2011 Standout
PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors
2006
High burden and pervasive positive selection of somatic mutations in normal human skin
2015 StandoutScience
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration
2010
Bone grafts and biomaterials substitutes for bone defect repair: A review
2017 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix
2000
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
2005
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
2009
Fracture healing: mechanisms and interventions
2014 Standout
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
2001 Standout
FGFR3 mutations in prostate cancer: association with low-grade tumors
2009
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
2012
Sox9 Modulates Proliferation and Expression of Osteogenic Markers of Adipose-Derived Stem Cells (ASC)
2013 Standout
A view on drug resistance in cancer
2019 StandoutNature
The FGF family: biology, pathophysiology and therapy
2009 Standout
The incidence of thanatophoric dysplasia mutations inFGFR3 gene is higher in low-grade or superficial bladder carcinomas
2001
Advances and challenges in targeting FGFR signalling in cancer
2017
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma
2004
FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway
2007
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α
2002
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
2007
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
2005 StandoutNature
A Crucial Role for Fibroblast Growth Factor Signaling in Embryonic Mammary Gland Development
2004
Reaching a Genetic and Molecular Understanding of Skeletal Development
2002 Standout
Cellular signaling by fibroblast growth factor receptors
2005 Standout
Fibroblast Growth Factor Receptor 3 Mutations in Epidermal Nevi and Associated Low Grade Bladder Tumors
2007
FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease
2002 Standout
Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors
2010
WHY HAS THE SURVIVAL OF PATIENTS WITH BLADDER CANCER NOT IMPROVED?
2007
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
2002
Fibroblast growth factor signalling: from development to cancer
2010 Standout
FGFR3 targeting strategies for achondroplasia
2012
SomaticFGF9mutations in colorectal and endometrial carcinomas associated with membranousβ-catenin
2007
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
2012
FGFR2 gene amplification and clinicopathological features in gastric cancer
2012
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
2016 Standout
RTK mutations and human syndromes
2000
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer
2013
Bladder cancer
2016 Standout
A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos
2000
A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation
2005
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
2007
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Sixteen years and counting: The current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias
2011
Mosaicism of activatingFGFR3 mutations in human skin causes epidermal nevi
2006
The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey
2008 StandoutNobel
Portrait of PTEN: Messages from mutant mice
2008 StandoutNobel
Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma
2011
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
2001
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
2000
Recent advances in bone tissue engineering scaffolds
2012 Standout
Fibroblast growth factor receptors, developmental corruption and malignant disease
2013
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
2016 Standout
microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3
2011
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
2005
Cancer-related inflammation and treatment effectiveness
2014 Standout
Paths of FGFR-driven tumorigenesis
2009
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
2005
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
2009
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans
2005
The role of fibroblast growth factors and their receptors in prostate cancer
2004
Genomics: a preview of genomic medicine
2008
FGF Receptor Mutations: Dimerization Syndromes, Cell Growth Suppression, and Animal Models
2000
Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture
2003 Standout
Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains
2001
Constitutive activating mutation of theFGFR3b in oral squamous cell carcinomas
2005
Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer.
2000
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
The Fibroblast Growth Factor signaling pathway
2015 Standout
Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation
2005
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
2001
Trends in stage‐specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006
2013
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
2012
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
2001
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
2003
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
2013
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
2002
Role of PTEN/PI3K pathway in endothelial cells
2007 StandoutNobel
Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor–Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell Lines
2005
PIK3CA MUTATIONS ARE AN EARLY GENETIC ALTERATION ASSOCIATED WITH FGFR3 MUTATIONS IN SUPERFICIAL PAPILLARY BLADDER TUMORS
2006
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML
2004
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors
2009
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
2015
Enhanced Bone Regeneration Associated With Decreased Apoptosis in Mice With Partial HIF-1α Deficiency
2006 StandoutNobel
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
2007
FGFR4 Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer
2006
Fibroblast Growth Factor Signaling and Basement Membrane Assembly Are Connected during Epithelial Morphogenesis of the Embryoid Body
2001
Cancer Genome Landscapes
2013 StandoutScience
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
2015
Impaired Fracture Healing in the Absence of TNF-α Signaling: The Role of TNF-α in Endochondral Cartilage Resorption
2003
RTK mutations and human syndromes: when good receptors turn bad
2000
Role of FGF Receptors as an Emerging Therapeutic Target in Lung Squamous Cell Carcinoma
2013
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
2006
Fibroblast Growth Factors and Their Receptors in Transitional Cell Carcinoma
2003
Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas
2006
Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
2014
Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation
2009
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells
2001
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.
2001
Works of J.-S. Bourdin being referenced
Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.
2005
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
1999